Pharmaceutical stocks are the large, established companies that develop, make and sell approved medicine. Unlike biotech they have finished products on the market and earnings that run year after year. That makes them some of the market's steadiest shares — but they live on patents, which expire, and on a pipeline that has to replace them. Below, our model ranks every US-listed pharmaceutical stock by score and momentum.
| Stock | Momentum | Score | To target |
|---|---|---|---|
| Amphastar PStrong | 88 | 227 | -13% |
| Bristol-Myers Squibb CompanyStrong | 66 | 224 | +9% |
| Medtronic plcStrong | 78 | 223 | +10% |
| Amgen IncStrong | 88 | 212 | -8% |
| Pfizer IncAverage | 88 | 209 | -1% |
| Novo Nordisk A/SAverage | 29 | 204 | +17% |
| Eli Lilly and CompanyAverage | 86 | 196 | +5% |
| Viatris IncAverage | 91 | 196 | +5% |
| InMode LtdAverage | 60 | 195 | +14% |
| AbbVie IncAverage | 94 | 191 | -1% |
| Johnson & JohnsonAverage | 71 | 190 | +9% |
| Globus Medical, IncAverage | 46 | 188 | +31% |
| Novartis AGAverage | 66 | 188 | +2% |
| Sanofi ADRAverage | 48 | 187 | +32% |
| Eton Pharmaceuticals, IncAverage | 82 | 163 | +41% |
| Abbott LaboratoriesAverage | 55 | 162 | +15% |
| Gilead Sciences, IncAverage | 91 | 158 | +2% |
| Teva Pharma Industries Ltd ADRAverage | 92 | 158 | +9% |
| Boston Scientific CorporationAverage | 13 | 155 | +35% |
| Tactile Systems Technology, IncAverage | 30 | 155 | +73% |
| Xeris Pharmaceuticals, IncWeak | 94 | 148 | +24% |
| Bruker CorporationWeak | 76 | 139 | +16% |
| Merck & Co., IncWeak | 86 | 128 | +8% |
| Insulet CorporationWeak | 12 | 128 | +18% |
| Aurora Cannabis IncWeak | 49 | 109 | +56% |
| Butterfly Network, Inc.Weak | 76 | 87 | +54% |
| Tilray, IncWeak | 3 | 79 | +111% |
| Zomedica Corp.Weak | 20 | 71 | no target |
| Canopy Growth CorporationWeak | 8 | 61 | +68% |
| Hims & Hers Health, IncWeak | 22 | 51 | +11% |
These are companies with approved medicine in sale and usually a broad range, so one disappointment does not sink the business. Johnson & Johnson, Pfizer, Bristol-Myers Squibb and Amgen are among the largest US-listed, and Novo Nordisk reaches the market as a depositary receipt. The theme also holds device and diagnostics companies such as Medtronic, which sell equipment rather than medicine and therefore follow different cycles.
The patent cliff. When a large product loses protection, generics take the market and the revenue falls quickly. The date is known years ahead, so the question is always what replaces it.
The pipeline. What is in development decides whether the company grows past the cliff. That makes trial results matter here too, just less violently than in biotech.
Pricing and politics. Governments and insurers negotiate what medicine costs. A change in the rules can move the whole sector at once.
Acquisitions. Buying a biotech is the standard way to fill a gap, and a big deal changes both the balance sheet and the growth outlook.
Largely, yes: people buy medicine whether the economy is strong or weak, so revenue is steadier than in most sectors. But they carry a risk defensives usually do not — a patent expiry or a failed trial can change the outlook sharply.
The point where a medicine loses patent protection and cheaper copies are allowed. Revenue from that product typically falls fast. Because the date is known in advance, the market judges the company on what is ready to take over.
Pharma companies are large and established, with approved products and running earnings. Biotech companies are typically smaller, still developing, and often not yet profitable — so they swing far more in both directions.
Because they sell into the same health care market. But a device company earns from equipment sales and hospital budgets rather than from patents, so it follows a different cycle. Check the individual stock page for what each company actually lives on.